stori remain compel sustain top-lin growth
bp om expans dd ep growth repres top-tier trajectori posit
lotu outcom re-bak back expect still repres upsid
forecast appreci setup believ high end bsx organ
revenu growth guidanc rang achiev
top-lin acceler like
top line forecast line consensu estim
review revenu build line item line item believ high end
organ growth guidanc rang highli achiev also find solac
manag track record start year strong set attain expect
rais guidanc past two year conjunct
quarterli beat gener organ revenu growth vs
impli midpoint guidanc rang deliv organ
top-lin growth perform vs midpoint guidanc rang full-year
organ top-lin guidanc rais call forecast
full-year guidanc increas top end organ growth rang
organ revenu growth guidanc rang put
place see top end rang achiev howev
like need exceed growth result serv catalyst consid
run-up print came organ growth perform
challeng comp year face comp
bp lighter nice posit featur top-lin setup
challeng om comparison fulli account consensu expect
bottom line face toughest earn growth comp year
ep cc result includ massiv bp margin expans om result
last year om perform led strongest gm experi
despit neg bp fx impact gm improv due strong
oper improv rhythm manag well favor product mix
particular watchman strength men health franchis
ep guidanc rang repres growth impli wide rang om
expans level depend top-lin growth assumpt howev margin expans
expect temper street om estim
contract appear reason estim even conserv
although optic om contract even flat om perform unlik ignit
investor fire expect appropri set account challeng
comp top ep guidanc rang appear highli achiev stronger-than-
expect top-lin experi thu street estim exceed
pleas see page report import disclosur
one three cardio rhythm manag space
seen sign stabil past sever quarter return single-digit
constant currenc top-lin growth accompani margin expans initi
stabil market robust pipelin product meaning contribut
revenu factor increas convict compani continu
outperform large-cap med devic peer
roll-out year-end
ce mark lotu
fda approv lotu
maintain market share
mri-saf pacemak
om expans
driven mri-saf approv
drive continu share gain face
structur heart driver tavr
top-lin growth exceed top
end rang lrp
market share loss
de market continu declin along
synergi share loss
weaker lotu watchman
global medic devic compani offer product
cardiovascular peripher intervent electrophysiolog endoscopi urology/
women health neuromodul busi unit compani vast product portfolio
pipelin allow expand new adjac market asthma atrial
fibril hypertens tavr parkinson diseas variou strategi initi
play continu mid-single-digit revenu growth bsx main competitor
busi abbott
potenti bid provid spark boston stori due heat
although potenti bid major stock catalyst intraquart half
appreci share occur front news investor seemingli
regain confid lotu return fold potenti top-lin growth
acceler rest histor revenu growth
guidanc rang bp annual om expans dd ep
growth seem fulli back tabl eye investor remain
conserv kept lotu contribut model lotu repres upsid
estim seem fulli bake posit investor sentiment
build sinc report pick specul around acquisit
offer poke surfac earli june arent expect lotu updat
call unlik comment devic pass compani intern
technic test hurdl confid move forward
regulatori pathway reinstat clinic intern pma submiss
top-lin organ growth guidanc repres sequenti
acceler midpoint rang primari driver bp softer top-
line growth comparison includ organ revenu growth medsurg vs
includ neuromod cardiovascular vs rhythm manag
vs come growth perform tougher
comp vs view midpoint revenu guidanc rang
bottom line face toughest earn growth comp year
ep cc result includ bp expans challeng ep om comp
ration consid street expect om contract drive
ep result ep growth view highli achiev
rais target remain outperform
prior price target repres ep forecast appli
price-to-earnings multipl ep forecast yield new price target share
repres approxim upsid current level view
attract believ assign multipl reason given increas confid
top-lin acceler play revenu growth trajectori sustain
along accompani bp om expans low dd
mid-teen ep growth although quit adept execut strateg tuck-
in constrain balanc sheet significantli improv access allow
manag bolster growth trajectori compani core franchis
expect bsx diversifi busi model continu deliv solid result view
setup justifi remain bullish name
figur cowen consensu estim
cowen compani thomson eikon cowen compani
cowen consensu estim mm exclud manag good incom ex interest expens expens estimatesconsensusprior quarterprior year cowen
compani report thomson eikon cowen compani
incom statement mm except per share good incom total interest pre-tax tax net incom ep net ep share exclud one-tim item includ exclud one-tim item amort cowen
compani report thomson eikon cowen compani
compani report thomson eikon cowen compani
compani report thomson eikon cowen compani
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
continu util pressur account organ play bigger
role health care deliveri competit dynam global potenti regulatori delay
reject failur devic clinic trial econom sensit price pressur
and/or weaken consum demand develop market econom and/or polit
uncertainti emerg market intellectu properti challeng
continu util pressur competit dynam global potenti
regulatori delay reject failur devic clinic trial lotu valv vessix
and/or weaken demand develop market econom and/or polit uncertainti
emerg market post acquisit integr issu bard electrophysiolog
busi orbu neich win perman injunct germani versu de
technolog platform stj durata lead recal lead full stabil recoveri
busi fluctuat foreign exchang rate
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
